TY - JOUR T1 - Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer JF - Anticancer Research JO - Anticancer Res SP - 3659 LP - 3665 VL - 36 IS - 7 AU - KIMIHIRO YAMASHITA AU - HIROSHI HASEGAWA AU - MITSUGU FUJITA AU - MASAYASU NISHI AU - TOMOKO TANAKA AU - AKIRA ARIMOTO AU - SATOSHI SUZUKI AU - TAKASHI KAMIGAKI AU - YOSHIHIRO KAKEJI Y1 - 2016/07/01 UR - http://ar.iiarjournals.org/content/36/7/3659.abstract N2 - Background/Aim: For the application of invariant natural killer T (iNKT) cells in cancer therapy, the CD40-CD40L interaction is indispensable in administering alpha-galactosylceramide (αGalCer). We hypothesized that CD40 plays an important role in dendritic cells (DC) pulsed with αGalCer (DCGs) in the treatment of lung metastases. Materials and Methods: Wild-type (WT) and CD40−/− mice were treated with DCGs isolated from WT or CD40−/− mice in a B16F10 lung metastases model and NK and NKT cell activity in lungs and the spleen were examined. Results: DCG treatment improved WT mice survival but CD40−/− hosts received no survival benefit. Conversely, attenuation of a therapeutic effect in mice treated with CD40−/− DCGs was not observed. The functional activities of NK and NKT cells in DCG-treated CD40−/− mice were partially suppressed. Conclusion: Host CD40 is essential for DCG treatment to have a therapeutic effect on B16F10 lung metastases. ER -